Core Insights - The company reported a revenue of 1.21 billion yuan in 2024, reflecting a growth of 1.6%, and a net profit attributable to shareholders of 502 million yuan, up by 2% [1] - The company experienced robust performance in overseas sales, with a significant increase of 99.4% in international revenue [4] Financial Performance - Quarterly revenue for 2024 was as follows: Q1: 360 million yuan (+25.4%), Q2: 430 million yuan (+27.7%), Q3: 180 million yuan (-31.7%), Q4: 240 million yuan (-20.8%) [2] - The net profit for each quarter was: Q1: 180 million yuan (+47.6%), Q2: 220 million yuan (+41.7%), Q3: 150 million yuan (+37.6%), Q4: -50 million yuan (-149.3%) [2] - The gross profit margin for 2024 was 73%, a decrease of 3.4 percentage points, while the net profit margin remained stable at 41.6% [2] Product Development - The company’s innovative products, including the Castor branched aortic stent and Minos abdominal aortic stent, have seen rapid growth in market acceptance and sales volume [3] - New products such as the Talos straight thoracic aortic stent system and Fontus branched intraoperative stent system have also shown significant growth in hospital admissions and implant volumes [3] Global Expansion - The company’s products are now sold in 40 countries and regions, with successful first implants of key products in multiple countries [4] - The Castor branched stent has been implanted in Colombia, Greece, and Belgium, while the Minos stent has been introduced in South Korea and Uzbekistan [4] Future Outlook - The company forecasts earnings per share (EPS) of 5.14 yuan, 6.45 yuan, and 8 yuan for the years 2025 to 2027, indicating a positive outlook for growth driven by an increase in innovative device sales [4]

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 心未来 2025年3月26日，国家药品监督管理局批准了 湖南埃普特医疗器械有限公司 （简称" 埃普特医疗 "） 的" 一次性使用压力监测射频消融导管 "（国械注准20253010659）的创新产品注册申请。 该产品由头端、管身、手柄、线缆、盐水接头和光电混合插头组成， 与上 海宏桐实业有限公司 （简称" 宏桐 实业 "）的 心脏射频消融仪 配合使用，主要用于 药物难治性、复发性、症状性的阵发性房颤 的治疗。 一次性使用压力监测射频消融导管通过 内置光学压力传感器 ，实现临床使用过程中压力的实时监测和反馈， 确保消融效果稳定性。 该产品可有效降低术中导管与组织贴靠过紧造成蒸汽爆裂或贴靠不足引起消融不完全等风险，使更多阵发性房 颤的患者受益。 埃普特医疗和宏桐实业均为 深圳惠泰医疗器械股份有限公司 （简称" 惠泰医疗 "）的全资子公司。 # 研发背景 房颤患病人群基数庞大，受人口老龄化加剧影响， 预计到2025年，房颤患病人数将达到2266.6万人 ，202 ...